
Download and complete the Enrollment and Prescription Form and fax to: 855-423-0011
Strongly recommended by AAD and AAAAI guidelines as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients1,2
LEO Pharma is committed to helping ensure that patients can access and initiate therapy when prescribed Adbry, including through the Adbry® advocate® Program. Restrictions apply.
See Full Terms, Conditions, and Eligibility Rules. For eligible patients, the Program consists of:
aThe initial dose of Adbry may be shipped either to your office or to the patient after submission of a completed Enrollment and Prescription Form or annual Healthcare Provider eRx Program Certification Form, as applicable, and Patient Authorization. A program representative will coordinate shipment to a patient, which may extend delivery time. Patients who have been initiated on therapy with samples are not eligible for Rapid Access Product.
bAdditional terms, conditions, and eligibility rules apply. Enrollment in Adbry Advocate is not required to obtain copay support. For all other patient support programs, enrollment in Adbry Advocate is required. Patient or healthcare provider may not seek reimbursement for the benefit received from any party. LEO Pharma reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.
cPatient is not eligible for the Program if enrolled in any federally or state funded health care program, including but not limited to Medicare (including Medicare Part D), Medicaid, VA, DOD, TRICARE or CHIP.
dIncome eligibility requirements apply. Patient may be required to submit documentation of income and insurance coverage status.
*Program has an annual cap. Program may not be combined with any third-party rebate, coupon or offer.
MOA Video
Actor portrayal.
Adbry Autoinjector Administration for Adults
Adbry Prefilled Syringe Administration for Adults
Adbry Administration for Children 12 Years and Older
ASSESSMENT SCALES
Example representation of IGA scoring. Not an actual patient.
The NRS is composed of one item and represents the numbers 0 (“no itch”) to 10 (“worst imaginable itch”). Subjects are asked to rate the intensity of their itch using this scale.
ADBRY® (tralokinumab-Idrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.
Please see full Prescribing Information.
1. Davis DMR, et al. J Am Acad Dermatol. 2024:90(2):e43-e56. doi:10.1016/j.jaad.2023.08.102 2. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, et al. Ann Allergy Asthma Immunol. 2024;132(3):274-312. doi:10.1016/j.anai.2023.11.009 3. Data on file. LEO Pharma Inc. 4. Blauvelt A, et al. Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control. Poster presented at: 32nd annual Congress of the European Academy of Dermatology and Venereology (EADV): October 11-14, 2023; Berlin, Germany. 5. Blauvelt A, et al. Long-term safety and efficacy of tralokinumab in adults and adolescents with moderate-to-severe atopic dermatitis treated for up to 6 years. Poster presented at: 44th Annual Fall Clinical Dermatology Congress: October 24-27, 2024; Las Vegas, NV. 6. ADBRY. Prescribing information. LEO Pharma Inc. 7. Reich K, et al. Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials. Poster presented at: Revolutionizing Atopic Dermatitis (RAD) Conference; April 29-May 1, 2023; Washington, DC. 8. Bieber T. Allergy. 2020;75(1):54-62. doi:10.1111/all.13954 9. Tsoi LC, et al. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018 10. Kim BE, et al. Clin Immunol. 2008;126(3):332-337. doi:10.1016/j.clim.2007.11.006 11. Szegedi K, et al. J Eur Acad Dermatol Venereol. 2015;29(11):2136-2144. doi:10.1111/jdv.13160 12. Popovic B, et al. J Mol Biol. 2017;429(2):208-219. doi:10.1016/j.jmb.2016.12.005 13. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-449. doi:10.1111/bjd.19574 14. Silverberg JI, et al. Br J Dermatol. 2021;184(3):450-463. doi:10.1111/bjd.19573 15. Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912. doi:10.1001/jamadermatol.2018.1572 16. Soung J, et al. Tralokinumab formulated as a pre-filled pen was efficacious and well-tolerated in adults and adolescents with moderate-to-severe atopic dermatitis. Poster presented at: Winter Clinical Dermatology Conference; February 16-19, 2024; Miami, FL. 17. Paller AS, et al. JAMA Dermatol. 2023;159(6):596-605. doi:10.1001/jamadermatol.2023.0627 18. Hanifin JM, et al. Exp Dermatol. 2001;10(1):11-18. doi:10.1034/j.1600-0625.2001.100102.x 19. Leshem YA, et al. Br J Dermatol. 2015;172(5):1353-1357. doi:10.1111/bjd.13662 20. Chopra R, et al. Br J Dermatol. 2017;177(5):1316-1321. doi:10.1111/bjd.15641 21. Futamura M, et al. J Am Acad Dermatol. 2016;74(2):288-294. doi:10.1016/j.jaad.2015.09.062 22. Phan NQ, et al. Acta Derm Venereol. 2012;92(5):502-507. doi:10.2340/00015555-1246 23. Silverberg JI, et al. Dermatol Clin. 2017;35(3):327-334. doi:10.1016/j.det.2017.02.005 24. Weidinger S, et al. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z